AR070783A1 - Forma de cristal de derivados de fenilamina-pirimidina - Google Patents
Forma de cristal de derivados de fenilamina-pirimidinaInfo
- Publication number
- AR070783A1 AR070783A1 ARP090100757A ARP090100757A AR070783A1 AR 070783 A1 AR070783 A1 AR 070783A1 AR P090100757 A ARP090100757 A AR P090100757A AR P090100757 A ARP090100757 A AR P090100757A AR 070783 A1 AR070783 A1 AR 070783A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystal
- phenylamine
- crystal form
- pyrimidine derivatives
- xrpd
- Prior art date
Links
- XQMIGRUKENWSIJ-UHFFFAOYSA-N aniline;pyrimidine Chemical class C1=CN=CN=C1.NC1=CC=CC=C1 XQMIGRUKENWSIJ-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 7
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a una forma particular de la (3,5-bis-trifluorometil)-N-[4-metil-3-(4-piridin-3-iI-pirimidin-2-il-amino)-fenil]-benzamida (formula 1), a los procesos para la preparacion de la misma, a composiciones farmacéuticas que contienen esta forma de cristal y a su uso como un agente antitumoral en humanos. El compuesto de la formula 1, también conocido como AN-019, es: (Formula 1). Reivindicacion 2: El cristal de la forma III de acuerdo con la reivindicacion 1, caracterizado porque el cristal de la forma III tiene las características de XRPD: (Tabla 2). Reivindicacion 17: El cristal de la forma 1 de acuerdo con la reivindicacion 16, caracterizado porque el cristal de la forma 1 tiene las características de XRPD: (Tabla 3). Reivindicacion 19: El cristal de la forma II de acuerdo con la reivindicacion 18, caracterizado porque el cristal de la forma II tiene las características de XRPD: (Tabla 4).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/042,247 US8067422B2 (en) | 2008-03-04 | 2008-03-04 | Crystal form of phenylamino pyrimidine derivatives |
| US12/042,235 US8183253B2 (en) | 2004-09-09 | 2008-03-04 | Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070783A1 true AR070783A1 (es) | 2010-05-05 |
Family
ID=40802116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100757A AR070783A1 (es) | 2008-03-04 | 2009-03-04 | Forma de cristal de derivados de fenilamina-pirimidina |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2265599B1 (es) |
| JP (1) | JP2011513380A (es) |
| KR (1) | KR20100126464A (es) |
| CN (1) | CN102015681B (es) |
| AP (1) | AP2651A (es) |
| AR (1) | AR070783A1 (es) |
| AU (1) | AU2009220856B2 (es) |
| CA (1) | CA2716413A1 (es) |
| CO (1) | CO6300946A2 (es) |
| EA (1) | EA019223B1 (es) |
| GE (1) | GEP20135882B (es) |
| IL (1) | IL207750A0 (es) |
| MA (1) | MA32142B1 (es) |
| MX (1) | MX2010009401A (es) |
| MY (2) | MY183331A (es) |
| NZ (1) | NZ587518A (es) |
| WO (1) | WO2009109867A2 (es) |
| ZA (1) | ZA201005957B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| HUE035059T2 (hu) | 2009-11-05 | 2018-05-02 | Rhizen Pharmaceuticals S A | Új benzopirán-kinát modulátorok |
| GB2488788B (en) | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| US9110310B2 (en) | 2011-03-18 | 2015-08-18 | Johnson & Johnson Vision Care, Inc. | Multiple energization elements in stacked integrated component devices |
| US10451897B2 (en) | 2011-03-18 | 2019-10-22 | Johnson & Johnson Vision Care, Inc. | Components with multiple energization elements for biomedical devices |
| ES2710874T3 (es) | 2011-05-04 | 2019-04-29 | Rhizen Pharmaceuticals S A | Compuestos novedosos como moduladores de proteína cinasas |
| SMT201900334T1 (it) | 2012-07-04 | 2019-07-11 | Rhizen Pharmaceuticals S A | Inibitori selettivi di pi3k delta |
| US9715130B2 (en) | 2014-08-21 | 2017-07-25 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form separators for biocompatible energization elements for biomedical devices |
| US9941547B2 (en) | 2014-08-21 | 2018-04-10 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes and cavity structures |
| US10627651B2 (en) | 2014-08-21 | 2020-04-21 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers |
| US9599842B2 (en) | 2014-08-21 | 2017-03-21 | Johnson & Johnson Vision Care, Inc. | Device and methods for sealing and encapsulation for biocompatible energization elements |
| US10381687B2 (en) | 2014-08-21 | 2019-08-13 | Johnson & Johnson Vision Care, Inc. | Methods of forming biocompatible rechargable energization elements for biomedical devices |
| US10361405B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes |
| US10361404B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Anodes for use in biocompatible energization elements |
| US9383593B2 (en) | 2014-08-21 | 2016-07-05 | Johnson & Johnson Vision Care, Inc. | Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators |
| US9793536B2 (en) | 2014-08-21 | 2017-10-17 | Johnson & Johnson Vision Care, Inc. | Pellet form cathode for use in a biocompatible battery |
| US10345620B2 (en) | 2016-02-18 | 2019-07-09 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices |
| SG11202103984WA (en) | 2018-10-23 | 2021-05-28 | Japan Science & Tech Agency | PPARd activator |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005281299B2 (en) * | 2004-09-09 | 2012-03-15 | Natco Pharma Limited | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase |
-
2009
- 2009-03-02 CN CN2009801160310A patent/CN102015681B/zh not_active Expired - Fee Related
- 2009-03-02 MX MX2010009401A patent/MX2010009401A/es active IP Right Grant
- 2009-03-02 CA CA2716413A patent/CA2716413A1/en not_active Abandoned
- 2009-03-02 AP AP2010005390A patent/AP2651A/xx active
- 2009-03-02 MY MYPI2010004153A patent/MY183331A/en unknown
- 2009-03-02 KR KR1020107021992A patent/KR20100126464A/ko not_active Withdrawn
- 2009-03-02 WO PCT/IB2009/005421 patent/WO2009109867A2/en not_active Ceased
- 2009-03-02 EA EA201071019A patent/EA019223B1/ru not_active IP Right Cessation
- 2009-03-02 GE GEAP200911960A patent/GEP20135882B/en unknown
- 2009-03-02 NZ NZ587518A patent/NZ587518A/xx not_active IP Right Cessation
- 2009-03-02 MY MYPI2014002513A patent/MY175373A/en unknown
- 2009-03-02 EP EP09716746.4A patent/EP2265599B1/en not_active Not-in-force
- 2009-03-02 JP JP2010549212A patent/JP2011513380A/ja active Pending
- 2009-03-02 AU AU2009220856A patent/AU2009220856B2/en not_active Ceased
- 2009-03-04 AR ARP090100757A patent/AR070783A1/es not_active Application Discontinuation
-
2010
- 2010-08-20 ZA ZA2010/05957A patent/ZA201005957B/en unknown
- 2010-08-23 IL IL207750A patent/IL207750A0/en unknown
- 2010-09-02 CO CO10108728A patent/CO6300946A2/es not_active Application Discontinuation
- 2010-09-03 MA MA33147A patent/MA32142B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009109867A2 (en) | 2009-09-11 |
| CN102015681B (zh) | 2013-08-28 |
| CN102015681A (zh) | 2011-04-13 |
| AU2009220856A2 (en) | 2010-09-16 |
| AU2009220856A1 (en) | 2009-09-11 |
| KR20100126464A (ko) | 2010-12-01 |
| AP2651A (en) | 2013-04-25 |
| GEP20135882B (en) | 2013-07-25 |
| AU2009220856B2 (en) | 2012-07-26 |
| CO6300946A2 (es) | 2011-07-21 |
| EP2265599B1 (en) | 2013-11-20 |
| MY183331A (en) | 2021-02-18 |
| EA201071019A1 (ru) | 2011-08-30 |
| MX2010009401A (es) | 2010-09-24 |
| WO2009109867A3 (en) | 2009-12-17 |
| NZ587518A (en) | 2012-09-28 |
| IL207750A0 (en) | 2010-12-30 |
| CA2716413A1 (en) | 2009-09-11 |
| EP2265599A2 (en) | 2010-12-29 |
| AP2010005390A0 (en) | 2010-10-31 |
| JP2011513380A (ja) | 2011-04-28 |
| MA32142B1 (fr) | 2011-03-01 |
| ZA201005957B (en) | 2011-10-26 |
| EA019223B1 (ru) | 2014-02-28 |
| MY175373A (en) | 2020-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070783A1 (es) | Forma de cristal de derivados de fenilamina-pirimidina | |
| NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
| UY30444A1 (es) | Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos. | |
| DOP2014000133A (es) | Triazolopiridinas sustituidas | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
| SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
| ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| EA201001488A1 (ru) | Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с сатурацией в с-кольце | |
| CR10192A (es) | Compuestos de amido y su uso como productos farmaceuticos | |
| UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
| CO6351777A2 (es) | Compuestos de tetraciclina sustituidod con fluor en c7 | |
| CU20120171A7 (es) | Triazolopiridinas sustituidas | |
| CR20110318A (es) | Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos | |
| CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
| UY32704A (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| CR20150432A (es) | Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
| UY30856A1 (es) | Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk | |
| UY32052A (es) | 5-aminopirazoles sustituidos y uso de los mismos | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| UY29325A1 (es) | Nuevos derivados de 2 - amino-piridina | |
| BR112015023878A2 (pt) | composto, composição farmacêutica, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |